Poster_Presentation_for_Wounds UK 2017 See the poster presented by Graham Bowen at the Wounds UK Annual Conference November 5-7, 2017 at Harrogate
Methods: 8 patients, 7 with type 2 and 1 with type 1 diabetes were selected, HbA1c range from 65-112 mmol/mol, who presented with a range of DFUs (neuropathic and ischaemic). Each patient was advised to use the FlowAid FA 100 device for a period of 4-6 weeks, and to use the device 2 twice a day for a period of 1-2 hours. At each Podiatry appointments, DFUs were assessed as per standard care. Each patient was asked to keep a pain diary, by means of a Visual analogue scale (VAS), record any positive or negative experiences and describe any improvements in their quality of life as a result of using FlowAid100.
Results: All 8 completed the evaluation with two extending the evaluation period by a further 4 weeks, with one extending to 3 months; 2 ischaemic patients reported a reducing in their VAS pain score from 8 to 5. 2 patients reported a return of sensation in neuropathy and clinically, improvements were noted in wound bed presentation and wound size reduction in all patients selected
One patient 50 years with type 2 diabetes who presented with a significant chronic >12 months heel DFU (SINBAD score of 5) made significant progress to full resolution after staring using FlowAid FA100 in conjunction with other treatment options. This prevented this patient from being admitted / progressing on to elective amputation. The edge of the wound once FlowAid FA 100 was activated, showed an increase in perfusion and the patient reported his foot feeling warmer.
FlowAid FA100 has a place in the management and prevention of diabetic foot disease. During the vascular assessment of the 8 patients in the evaluation, as soon as the device was activated, there was a significant audible improvement in Doppler sound in all the pedal pulses.
A larger scale study is indicated to look at the cost benefits of the FlowAid FA100 for a greater range of DFUs. Wider Implications for use of this device would be in those groups of patients identified at Moderate and High Risk (NICE 2016) as the long term benefits of using the device in improving circulation may well yield both significant financial savings in the long term for this group of patients in the management of impaired vascular and neuropathy in the diabetic foot.